VKTX Price / Book | Viking Therapeutics, Inc.

Viking Therapeutics, Inc. Price/Book Ratio

The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.

Viking Therapeutics, Inc. price/book ratio for the quarter ending 2026-06-30 was 11.14, a 197.82% increase year-over-year.
Viking Therapeutics, Inc. price/book ratio for the quarter ending 2026-03-31 was 7.51, a 134.66% increase year-over-year.
Viking Therapeutics, Inc. price/book ratio for the quarter ending 2025-12-31 was 6.32, a 23.90% increase year-over-year.
Viking Therapeutics, Inc. price/book ratio for the quarter ending 2025-09-30 was 4.14, a 46.46% decline year-over-year.
Viking Therapeutics, Inc. price/book ratio for fiscal 2026 was 11.14.
Viking Therapeutics, Inc. price/book ratio for fiscal 2025 was 6.32, a 23.90% increase from fiscal 2024.
Viking Therapeutics, Inc. price/book ratio for fiscal 2024 was 5.1, a 4.62% decline from fiscal 2023.
Viking Therapeutics, Inc. price/book ratio for fiscal 2023 was 5.35, a 5.64% increase from fiscal 2022.

Available history: 2015-06-30 to 2026-06-30
Data captured: 2026-06-30

Historical Price/Book Ratio

Date	Price/Book Ratio	Market capitalization	Shareholder equity
2026-06-30	11.14	$4.55B	$408.32M
2026-03-31	7.51	$3.77B	$501.92M
2025-12-31	6.32	$4.04B	$639.06M
2025-09-30	4.14	$2.96B	$713.03M
2025-06-30	3.74	$2.98B	$795.46M
2025-03-31	3.2	$2.71B	$846.92M
2024-12-31	5.1	$4.49B	$880.28M
2024-09-30	7.74	$7.05B	$911.45M
2024-06-30	6.38	$5.87B	$920.98M
2024-03-31	9.68	$9.04B	$933.89M
2023-12-31	5.35	$1.86B	$348.42M
2023-09-30	3.01	$1.11B	$368.24M
2023-06-30	4.2	$1.62B	$386.12M
2023-03-31	9.85	$1.32B	$134.07M
2022-12-31	5.06	$735.62M	$145.32M
2022-09-30	1.38	$208.59M	$151.29M
2022-06-30	1.34	$221.63M	$165.23M
2022-03-31	1.27	$232.12M	$182.27M
2021-12-31	1.78	$359.94M	$201.88M
2021-09-30	2.31	$491.32M	$213.12M
2021-06-30	2.08	$468.36M	$224.97M
2021-03-31	2.06	$488.15M	$237.22M
2020-12-31	1.69	$412.21M	$244.34M
2020-09-30	1.67	$424.4M	$253.79M
2020-06-30	2	$524.59M	$261.95M
2020-03-31	1.27	$339.59M	$268.28M
2019-12-31	2.1	$580.76M	$277.12M
2019-09-30	1.75	$497.12M	$283.49M
2019-06-30	2.08	$599.04M	$288.35M
2019-03-31	2.43	$715.95M	$294.57M
2018-12-31	1.84	$548.83M	$297.75M
2018-09-30	4.11	$1.24B	$302.05M
2018-06-30	4.1	$575.6M	$140.36M
2018-03-31	3.06	$222.58M	$72.63M
2017-12-31	10.8	$145.42M	$13.46M
2017-09-30	24.45	$54.43M	$2.23M
2017-06-30	4.54	$29.91M	$6.59M
2017-03-31	4.63	$34.93M	$7.55M
2016-12-31	3.08	$24.78M	$8.04M
2016-09-30	2.73	$27.87M	$10.22M
2016-06-30	1.9	$24.29M	$12.79M
2016-03-31	2.38	$13.75M	$5.77M
2015-12-31	3.78	$33.02M	$8.72M
2015-09-30	4.32	$57.33M	$13.27M
2015-06-30	4.02	$69.85M	$17.39M

Annual Price/Book Ratio

Date	Price/Book Ratio	Market capitalization	Shareholder equity
2026-06-30	11.14	$4.55B	$408.32M
2025-12-31	6.32	$4.04B	$639.06M
2024-12-31	5.1	$4.49B	$880.28M
2023-12-31	5.35	$1.86B	$348.42M
2022-12-31	5.06	$735.62M	$145.32M
2021-12-31	1.78	$359.94M	$201.88M
2020-12-31	1.69	$412.21M	$244.34M
2019-12-31	2.1	$580.76M	$277.12M
2018-12-31	1.84	$548.83M	$297.75M
2017-12-31	10.8	$145.42M	$13.46M
2016-12-31	3.08	$24.78M	$8.04M
2015-12-31	3.78	$33.02M	$8.72M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Indivior Pharmaceuticals, Inc. (INDV)		$4.250B	14.09
Tango Therapeutics, Inc. (TNGX)	United States	$4.154B	-42.53
Edgewise Therapeutics, Inc. (EWTX)	United States	$4.470B	-22.23
AbCellera Biologics Inc. (ABCL)		$3.879B	-14.59
ACADIA PHARMACEUTICALS INC (ACAD)	United States	$3.823B	11.45
Veradermics, Inc (MANE)	United States	$4.839B
Xenon Pharmaceuticals Inc. (XENE)		$3.684B	-14.27
Organon & Co. (OGN)	United States	$3.603B	17.03
IDEAYA Biosciences, Inc. (IDYA)	United States	$3.540B	-20.52
Erasca, Inc. (ERAS)	United States	$5.073B	-19.96